First Two Patients Enrolled in Pilot Clinical Trial Using Bone Biologics’ NB1 Bone Graft Device for Spine Fusion

Friday, June 21, 2024

Bone Biologics Corporation has initiated a multicenter pilot clinical study for its NB1 bone graft device. NB1 combines NELL-1 protein with demineralized bone matrix (DBM) to facilitate precise control over bone regeneration, specifically targeting degenerative disc disease (DDD).

The study aims to enroll 30 adult subjects undergoing transforaminal lumbar interbody fusion (TLIF) to evaluate NB1's safety, effectiveness in achieving fusion, pain reduction, functional improvement, and incidence of adverse events.

The first treatments have begun with two patients in Australia, following positive results from preclinical safety and efficacy studies conducted on animals.

Optimism about NB1's potential to meet the critical need for a bone growth product that operates selectively within the bone. He highlighted the significant market opportunity, estimated at $3 billion annually for spine fusion products.

Degenerative disc disease is a prevalent cause of lower back pain and poses substantial challenges to patient mobility and quality of life, particularly as the global population ages.

Bone Biologics anticipates that NB1, leveraging NELL-1's unique properties, will effectively address these challenges and compete effectively in the spine fusion market.

In addition to spine fusion, NB1 holds promise for treating trauma, osteoporosis, and other bone-related conditions, tapping into broader market segments potentially worth billions annually.

This development underscores Bone Biologics' strategic focus on advancing innovative solutions in orthobiologics.






Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress